# **SAFETY DATA SHEET**



Caspase-3 inhibitor Ac-DEVD-CHO, 5 mM (Caspase-3 inhibitor) (component of EarlyTox<sup>™</sup> Caspase-3/7 R110 Assay Kits)

## SECTION 1: Identification of the substance/mixture and of the company/ undertaking

1.1 Product identifier	
Product name	<ul> <li>Caspase-3 inhibitor Ac-DEVD-CHO, 5 mM (Caspase-3 inhibitor) (component of EarlyTox<sup>™</sup> Caspase-3/7 R110 Assay Kits)</li> </ul>
Product type	: Liquid.
Kit name	: EarlyTox™ Caspase-3/7 R110 Assay Bulk Kit EarlyTox™ Caspase-3/7 R110 Assay Explorer Kit Component: Caspase-3 inhibitor Ac-DEVD-CHO, 5 mM in DMSO
Kit part number	: R8347/R8346/R8346C/R8347C
1.2 Relevant identified us	es of the substance or mixture and uses advised against
Product use	: For R&D use only.
Area of application	: Industrial applications.

MOLECULAR DEVICES, LLC 3860 N First Street San Jose, CA 95134 USA	
e-mail address of person responsible for this SDS	: msdsinquiry@moldev.com

### **1.4 Emergency telephone number**

National advisory	<u>y body/Poison Centre</u>

Telephone number	: CHEMTREC (24 hours): 1-800-424-9300 (USA/Canada),
	+1 703-527-3887 (Outside USA/Canada)

## **SECTION 2: Hazards identification**

### 2.1 Classification of the substance or mixture

Product definition : Mixture

Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Not classified.

The product is not classified as hazardous according to Regulation (EC) 1272/2008 as amended.

**Ingredients of unknown** : 99.8 percent of the mixture consists of component(s) of unknown inhalation toxicity

See Section 11 for more detailed information on health effects and symptoms.

```
Date of issue/Date of revision
```

: 14/07/2015

Caspase-3 inhibitor Ac-DEVD-CHO, 5 mM (Caspase-3 inhibitor) (component of EarlyTox™ Caspase-3/7 R110 Assay Kits)

SECTION 2: Hazards	
2.2 Label elements	
Signal word	: No signal word.
Hazard statements	: No known significant effects or critical hazards.
Precautionary statements	
Prevention	: Not applicable.
Response	: Not applicable.
Storage	: Not applicable.
Disposal	: Not applicable.
Supplemental label elements	: Not applicable.
Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles	: Not applicable.
Special packaging requirem	<u>ents</u>
Containers to be fitted with child-resistant fastenings	: Not applicable.
Tactile warning of danger	: Not applicable.

### 2.3 Other hazards

Other hazards which do : None known. not result in classification

## **SECTION 3: Composition/information on ingredients**

**3.2 Mixtures** 

: Mixture

There are no ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

## SECTION 4: First aid measures

4.1 Description of first aid	measures
Eye contact	: Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Get medical attention if irritation occurs.
Inhalation	: Remove victim to fresh air and keep at rest in a position comfortable for breathing. Get medical attention if symptoms occur.
Skin contact	: Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention if symptoms occur.

Caspase-3 inhibitor Ac-DEVD-CHO, 5 mM (Caspase-3 inhibitor) (component of EarlyTox™ Caspase-3/7 R110 Assay Kits)

### **SECTION 4: First aid measures**

Ingestion	: Wash out mouth with water. Remove victim to fresh air and keep at rest in a position comfortable for breathing. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Do not induce vomiting unless directed to do so by medical personnel. Get medical attention if symptoms occur.
Protection of first-aiders	: No action shall be taken involving any personal risk or without suitable training.

### 4.2 Most important symptoms and effects, both acute and delayed

**Over-exposure signs/symptoms** 

Eye contact	: No specific data.
Inhalation	: No specific data.
Skin contact	: No specific data.
Ingestion	: No specific data.

### 4.3 Indication of any immediate medical attention and special treatment needed

Notes to physician	<ul> <li>Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.</li> </ul>
Specific treatments	: No specific treatment.

## **SECTION 5: Firefighting measures**

5.1 Extinguishing media	
Suitable extinguishing media	: Use an extinguishing agent suitable for the surrounding fire.
Unsuitable extinguishing media	: 🗹 not use water jet.
5.2 Special hazards arising f	rom the substance or mixture
Hazards from the substance or mixture	: In a fire or if heated, a pressure increase will occur and the container may burst.
Hazardous thermal decomposition products	: Decomposition products may include the following materials: carbon dioxide carbon monoxide sulfur oxides
5.3 Advice for firefighters	
Special protective actions	: Promptly isolate the scene by removing all persons from the vicinity of the incident if

for fire-fighters there is a fire. No action shall be taken involving any personal risk or without suitable training.

Caspase-3 inhibitor Ac-DEVD-CHO, 5 mM (Caspase-3 inhibitor) (component of EarlyTox™ Caspase-3/7 R110 Assay Kits)

### **SECTION 5: Firefighting measures**

Special protective equipment for fire-fighters	:	Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for
		chemical incidents.

## **SECTION 6: Accidental release measures**

6.1 Personal precautions, pro	oteo	ctive equipment and emergency procedures
For non-emergency personnel	:	No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Put on appropriate personal protective equipment.
For emergency responders	:	If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".
6.2 Environmental precautions	:	Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).
6.3 Methods and material for	CO	ntainment and cleaning up
Small spill	:	Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.
Large spill	:	Stop leak if without risk. Move containers from spill area. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with non-combustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations. Dispose of via a licensed waste disposal contractor.
6.4 Reference to other sections	:	See Section 1 for emergency contact information. See Section 8 for information on appropriate personal protective equipment. See Section 13 for additional waste treatment information.

## **SECTION 7: Handling and storage**

### 7.1 Precautions for safe handling

Protective measures	: Put on appropriate personal protective equipment (see Section 8).
Advice on general occupational hygiene	: Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

Caspase-3 inhibitor Ac-DEVD-CHO, 5 mM (Caspase-3 inhibitor) (component of EarlyTox™ Caspase-3/7 R110 Assay Kits)

## **SECTION 7: Handling and storage**

### 7.2 Conditions for safe storage, including any incompatibilities

To not store below the following temperature: 4°C (39.2°F). Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

### 7.3 Specific end use(s) Recommendations

: Not available.

Industrial sector specific solutions

## **SECTION 8: Exposure controls/personal protection**

: Not available.

### 8.1 Control parameters

**Occupational exposure limits** 

No exposure limit value known.

Recommended monitoring procedures

If this product contains ingredients with exposure limits, personal, workplace atmosphere or biological monitoring may be required to determine the effectiveness of the ventilation or other control measures and/or the necessity to use respiratory protective equipment. Reference should be made to monitoring standards, such as the following: European Standard EN 689 (Workplace atmospheres - Guidance for the assessment of exposure by inhalation to chemical agents for comparison with limit values and measurement strategy) European Standard EN 14042 (Workplace atmospheres - Guide for the application and use of procedures for the assessment of exposure to chemical agents) European Standard EN 482 (Workplace atmospheres - General requirements for the performance of procedures for the measurement of chemical agents) Reference to national guidance documents for methods for the determination of hazardous substances will also be required.

### **DNELs/DMELs**

No DNELs/DMELs available.

### **PNECs**

No PNECs available

### 8.2 Exposure controls

## Appropriate engineering controls

- : Good general ventilation should be sufficient to control worker exposure to airborne contaminants.
- Individual protection measures

Caspase-3 inhibitor Ac-DEVD-CHO, 5 mM (Caspase-3 inhibitor) (component of EarlyTox™ Caspase-3/7 R110 Assay Kits)

### **SECTION 8: Exposure controls/personal protection**

Hygiene measures	: Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.
Eye/face protection	: Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with side-shields.
Skin protection	
Hand protection	: Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary.
Body protection	<ul> <li>Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.</li> </ul>
Other skin protection	<ul> <li>Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.</li> </ul>
Respiratory protection	: Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.
Environmental exposure controls	: Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

## **SECTION 9: Physical and chemical properties**

### 9.1 Information on basic physical and chemical properties

<u>Appearance</u>		
Physical state	:	Liquid. [Clear.]
Colour	:	Colourless.
Odour	:	Not available.
Odour threshold	:	Not available.
рН	:	Not available.
Melting point/freezing point	:	Not available.
Initial boiling point and boiling	:	Not available.
range		
Flash point	1	Not available.
Evaporation rate	1	Not available.
Flammability (solid, gas)	:	Not available.

Caspase-3 inhibitor Ac-DEVD-CHO, 5 mM (Caspase-3 inhibitor) (component of EarlyTox™ Caspase-3/7 R110 Assay Kits)

d chamical proportios
nd chemical properties
: Not available.
: Easily soluble in the following materials: cold water and hot water.
: Not available.
: Not available.
: No additional information.

## **SECTION 10: Stability and reactivity**

comments

10.1 Reactivity	:	No specific test data related to reactivity available for this product or its ingredients.
10.2 Chemical stability	:	The product is stable.
10.3 Possibility of hazardous reactions	:	Under normal conditions of storage and use, hazardous reactions will not occur. Under normal conditions of storage and use, hazardous polymerisation will not occur.
10.4 Conditions to avoid	:	Keep away from heat, sparks and flame.
10.5 Incompatible materials	:	Reactive or incompatible with the following materials: oxidizing materials, reducing materials and moisture.
10.6 Hazardous decomposition products	:	Under normal conditions of storage and use, hazardous decomposition products should not be produced.

Caspase-3 inhibitor Ac-DEVD-CHO, 5 mM (Caspase-3 inhibitor) (component of EarlyTox™ Caspase-3/7 R110 Assay Kits)

11.1 Information on toxicolog	gical effects
Acute toxicity	
<b>Conclusion/Summary</b>	: Not available.
Acute toxicity estimates	
Not available.	
Irritation/Corrosion	
<b>Conclusion/Summary</b>	: Not available.
Sensitisation	
<b>Conclusion/Summary</b>	: Not available.
<b>Mutagenicity</b>	
Conclusion/Summary	: Not available.
Carcinogenicity	
Conclusion/Summary	: Not available.
Reproductive toxicity	
Conclusion/Summary	: Not available.
Teratogenicity	
Conclusion/Summary	: Not available.
Specific target organ toxicit	t <u>y (single exposure)</u>
Not available.	
	ty (repeated exposure)
Specific target organ toxicit	t <u>y (repeated exposure)</u>
Specific target organ toxicit Not available.	t <u>y (repeated exposure)</u>
Specific target organ toxicit Not available. Aspiration hazard	t <u>y (repeated exposure)</u>
Specific target organ toxicit Not available.	t <u>y (repeated exposure)</u>
Specific target organ toxicit Not available. Aspiration hazard	t <u>y (repeated exposure)</u>
Specific target organ toxicit Not available. Aspiration hazard Not available.	
Specific target organ toxicit Not available. Aspiration hazard Not available. Information on likely routes of exposure	: Not available.
Specific target organ toxicit Not available. Aspiration hazard Not available. Information on likely routes of exposure Potential acute health effects	: Not available.
Specific target organ toxicit Not available. Aspiration hazard Not available. Information on likely routes of exposure Potential acute health effects Eye contact	<ul> <li>No known significant effects or critical hazards.</li> </ul>
Specific target organ toxicit Not available. Aspiration hazard Not available. Information on likely routes of exposure Potential acute health effects Eye contact Inhalation	<ul> <li>No known significant effects or critical hazards.</li> <li>No known significant effects or critical hazards.</li> </ul>
Specific target organ toxicit Not available. Aspiration hazard Not available. Information on likely routes of exposure Potential acute health effects Eye contact	<ul> <li>No known significant effects or critical hazards.</li> </ul>
Specific target organ toxicit Not available. Aspiration hazard Not available. Information on likely routes of exposure Potential acute health effects Eye contact Inhalation	<ul> <li>No known significant effects or critical hazards.</li> <li>No known significant effects or critical hazards.</li> </ul>
Specific target organ toxicit Not available. Aspiration hazard Not available. Information on likely routes of exposure Potential acute health effects Eye contact Inhalation Skin contact Ingestion	<ul> <li>No known significant effects or critical hazards.</li> </ul>
Symptoms related to the physical sectors of the sector of	<ul> <li>No known significant effects or critical hazards.</li> </ul>
Specific target organ toxicit Not available. Aspiration hazard Not available. Information on likely routes of exposure Potential acute health effects Eye contact Inhalation Skin contact Ingestion Symptoms related to the phy Eye contact	<ul> <li>No known significant effects or critical hazards.</li> </ul>
Symptoms related to the physical sectors of the sector of	<ul> <li>No known significant effects or critical hazards.</li> </ul>

Date of issue/Date of revision

: 25/01/2018 Date of previous issue

Caspase-3 inhibitor Ac-DEVD-CHO, 5 mM (Caspase-3 inhibitor) (component of EarlyTox™ Caspase-3/7 R110 Assay Kits)

## **SECTION 11: Toxicological information**

#### Delayed and immediate effects as well as chronic effects from short and long-term exposure

<u>Short term exposure</u>	
Potential immediate effects	: Not available.
Potential delayed effects	: Not available.
Long term exposure	
Potential immediate effects	: Not available.
Potential delayed effects	: Not available.
Potential chronic health effe	ects
Not available.	
Conclusion/Summary	: Not available.
General	: No known significant effects or critical hazards.
Carcinogenicity	: No known significant effects or critical hazards.
Mutagenicity	: No known significant effects or critical hazards.
Teratogenicity	: No known significant effects or critical hazards.
<b>Developmental effects</b>	: No known significant effects or critical hazards.
Fertility effects	: No known significant effects or critical hazards.
Other information	: Not available.

12.1 Toxicity

### **SECTION 12: Ecological information**

Conclusion/Summary	: Not available.
12.2 Persistence and degr	adability
Conclusion/Summary	: Not available.
12.3 Bioaccumulative pote	ential
Not available.	
12.4 Mobility in soil	
Soil/water partition coefficient (Koc)	: Not available.
Mobility	: Not available.
12.5 Results of PBT and v	PvB assessment
PBT	: Not applicable.
vPvB	: Not applicable.

Caspase-3 inhibitor Ac-DEVD-CHO, 5 mM (Caspase-3 inhibitor) (component of EarlyTox™ Caspase-3/7 R110 Assay Kits)

## **SECTION 12: Ecological information**

12.6 Other adverse effects : No known significant effects or critical hazards.

## **SECTION 13: Disposal considerations**

### **13.1 Waste treatment methods**

Product	
Methods of disposal	The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.
Hazardous waste	Within the present knowledge of the supplier, this product is not regarded as hazardous waste, as defined by EU Directive 2008/98/EC.
Packaging	
Methods of disposal	The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.
Special precautions	This material and its container must be disposed of in a safe way. Empty containers or liners may retain some product residues. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.

### **SECTION 14: Transport information**

	ADR/RID	ADN	IMDG	ΙΑΤΑ
14.1 UN number	Not regulated.	Not regulated.	Not regulated.	Not regulated.
14.2 UN proper shipping name	-	-	-	-
14.3 Transport hazard class(es)	-	-	-	-
14.4 Packing group	-	-	-	-
14.5 Environmental hazards	No.	No.	No.	No.

#### 14.6 Special precautions for user

: Transport within user's premises: always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

Caspase-3 inhibitor Ac-DEVD-CHO, 5 mM (Caspase-3 inhibitor) (component of EarlyTox™ Caspase-3/7 R110 Assay Kits)

### **SECTION 14: Transport information**

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code : Not available.

## **SECTION 15: Regulatory information**

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

### EU Regulation (EC) No. 1907/2006 (REACH)

Annex XIV - List of substances subject to authorisation

### **Annex XIV**

None of the components are listed.

#### Substances of very high concern

None of the components are listed.

Annex XVII - Restrictions	1	Not applicable.
on the manufacture,		
placing on the market		
and use of certain		
dangerous substances,		
mixtures and articles		

#### **Other EU regulations**

Europe inventory	1	Not determined.
Industrial emissions	1	Listed
(integrated pollution		
prevention and control) -		

#### Air

Ozone depleting substances (1005/2009/EU) Not listed.

Not hoted.

### Prior Informed Consent (PIC) (649/2012/EU)

Not listed.

#### **Seveso Directive**

This product is not controlled under the Seveso Directive.

International regulations

Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

### Montreal Protocol (Annexes A, B, C, E)

Not listed.

Stockholm Convention on Persistent Organic Pollutants Not listed.

### Rotterdam Convention on Prior Informed Consent (PIC)

Not listed.

Caspase-3 inhibitor Ac-DEVD-CHO, 5 mM (Caspase-3 inhibitor) (component of EarlyTox™ Caspase-3/7 R110 Assay Kits)

## **SECTION 15: Regulatory information**

```
UNECE Aarhus Protocol on POPs and Heavy Metals
```

Not listed.

15.2 Chemical safety	1	This product contains substances for which Chemical Safety Assessments are still
assessment		required.
15.3 Registration status	:	Mixture. Information concerning the substance : Contact local supplier or distributor.

## **SECTION 16: Other information**

Indicates information that has changed from previously issued version.

Abbreviations and acronyms	: ATE = Acute Toxicity Estimate CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No. 1272/2008] DMEL = Derived Minimal Effect Level DNEL = Derived No Effect Level EUH statement = CLP-specific Hazard statement PBT = Persistent, Bioaccumulative and Toxic PNEC = Predicted No Effect Concentration RRN = REACH Registration Number vPvB = Very Persistent and Very Bioaccumulative
Key literature references and sources for data	<ul> <li>Regulation (EC) No. 1272/2008 [CLP]; European Agreement concerning the International Carriage of Dangerous Goods by Road (ADR), concluded in Geneva on 30 September 1957 plus amendments (Uniform text: Journal of Laws 27/2009 pos. 162 plus amendments); Regulation for the transport of dangerous materials on the Rhine (ADN); Occupational exposure limits; International regulations</li> </ul>

#### Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Classification	Justification		
Not classified.			

### Full text of abbreviated H statements

Not applicable.

### Full text of classifications [CLP/GHS]

Not applicable.

- **Training advice** : Ensure operatives are trained to minimise exposures. Training staff on good practice.
- Date of issue/ Date of : 25/01/2018

revision		
Date of previous issue	: 14/07/2015	

: 2

Version

Notice to reader

Date	of	issue/	Date	of	revision

Caspase-3 inhibitor Ac-DEVD-CHO, 5 mM (Caspase-3 inhibitor) (component of EarlyTox™ Caspase-3/7 R110 Assay Kits)

## **SECTION 16: Other information**

To the best of our knowledge, the information contained herein is accurate. However, neither the above-named supplier, nor any of its subsidiaries, assumes any liability whatsoever for the accuracy or completeness of the information contained herein.

Final determination of suitability of any material is the sole responsibility of the user. All materials may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only hazards that exist.